These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants]. Sánchez Luna M; Pérez Muñuzuri A; Leante Castellanos JL; Ruiz Campillo CW; Sanz López E; Benavente Fernández I; Sánchez Redondo MD; Rite Gracia S; An Pediatr (Engl Ed); 2019 Nov; 91(5):348-350. PubMed ID: 31585838 [No Abstract] [Full Text] [Related]
3. Comments on palivizumab (Synagis). Moler FW; Brown RW; Faix RG; Gilsdorf JR Pediatrics; 1999 Feb; 103(2):495-7. PubMed ID: 9925848 [No Abstract] [Full Text] [Related]
4. Nurse role in RSV management. Whelan B Early Hum Dev; 2012 May; 88 Suppl 2():S29-30. PubMed ID: 22633508 [No Abstract] [Full Text] [Related]
5. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry. Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J; Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822 [TBL] [Abstract][Full Text] [Related]
6. Optimal timing and dosing intervals of palivizumab in premature neonates: still some work to do. Manzoni P; Sala U; Gomirato G; Coscia A; Fabris C Pediatrics; 2005 May; 115(5):1439-40; author reply 1440-1. PubMed ID: 15867062 [No Abstract] [Full Text] [Related]
7. Re-evaluating the New Committee on Infectious Diseases Recommendations for Palivizumab Use in Premature Infants. Yogev R; Krilov LR; Fergie JE; Weiner LB Pediatr Infect Dis J; 2015 Sep; 34(9):958-60. PubMed ID: 26107347 [No Abstract] [Full Text] [Related]
8. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196 [TBL] [Abstract][Full Text] [Related]
9. The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis. Afghani B; Ngo T; Leu SY; Wu FL; Cecilio M; Aron-Johnson P; Zeitany R; Sills J; Amin A Pediatr Infect Dis J; 2006 Nov; 25(11):1019-24. PubMed ID: 17072124 [TBL] [Abstract][Full Text] [Related]
10. [Infections with RS viruses in children]. Krankenpfl J; 2004; 42(7-10):231. PubMed ID: 15675393 [No Abstract] [Full Text] [Related]
11. Prevention of respiratory syncytial virus infection with palivizumab. Thomas M; Bedford-Russell A; Sharland M Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088 [TBL] [Abstract][Full Text] [Related]
12. [Use of palivizumab in the prevention of syncytial virus respiratory infection]. Vagnarelli F; Magnani C; Vancini A; Bonacini G; Iori A; Mariani S; Attanasio M; Banchini G Acta Biomed Ateneo Parmense; 2000; 71 Suppl 1():573-5. PubMed ID: 11424809 [TBL] [Abstract][Full Text] [Related]
13. Use of palivizumab in Germany: data from 2002-2007. Simon A; Nowak H; Sterz R Klin Padiatr; 2011 Sep; 223(5):292-8. PubMed ID: 21509705 [TBL] [Abstract][Full Text] [Related]
14. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. ; Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315 [TBL] [Abstract][Full Text] [Related]
15. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections]. Scholz H Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169 [TBL] [Abstract][Full Text] [Related]
16. [Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)]. Figueras Aloy J; Carbonell Estrany X; An Pediatr (Barc); 2010 Aug; 73(2):98.e1-4. PubMed ID: 20621574 [TBL] [Abstract][Full Text] [Related]
17. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden. Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J Acta Paediatr; 2004 Nov; 93(11):1470-3. PubMed ID: 15513574 [TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. Yi H; Lanctôt KL; Bont L; Bloemers BL; Weijerman M; Broers C; Li A; Kiss A; Mitchell I; Paes B; Pediatrics; 2014 Jun; 133(6):1031-7. PubMed ID: 24799541 [TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009. Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095 [TBL] [Abstract][Full Text] [Related]
20. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Committee on Infectious Diseases Pediatrics; 2009 Dec; 124(6):1694-701. PubMed ID: 19736258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]